Epoprostenol
| Code | Size | Price |
|---|
| TAR-T20778-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Epoprostenol, a prostaglandin, is a powerful vasodilator. It inhibits platelet aggregation.
CAS:
35121-78-9
Formula:
C20H32O5
Molecular Weight:
352.471
Purity:
0.98
SMILES:
[H][C@@]12C[C@@H](O)[C@H](C=C[C@@H](O)CCCCC)[C@H]1CC(O2)=CCCCC(O)=O
References
1. Ahmad KA, Banales J, Henderson CL, Ramos SE, Brandt KM, Powers GC. Intravenous epoprostenol improves oxygenation index in patients with persistent pulmonary hypertension of the newborn refractory to nitric oxide. J Perinatol. 2018 Jul 25. doi: 10.1038/s41372-018-0179-7. [Epub ahead of print] PubMed PMID: 30046179.
2. Guan Z, Shen X, Zhang YJ, Li XG, Gao YF, Tan J, Yuan H, Liu JJ. Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery. Medicine (Baltimore). 2018 Jul;97(28):e10908. doi: 10.1097/MD.0000000000010908. PubMed PMID: 29995750.
3. Navaratnam M, Williams GD, Shuttleworth P, Almond C, Maeda K. Epoprostenol Therapy for a Pediatric Patient With Subacute Heparin-Induced Thrombocytopenia and a Ventricular Assist Device Undergoing Heart Transplant: A Case Report. A A Pract. 2018 Jul 5. doi: 10.1213/XAA.0000000000000818. [Epub ahead of print] PubMed PMID: 29985837.
4. Akagi S, Matsubara H, Nakamura K, Ito H. Modern treatment to reduce pulmonary arterial pressure in pulmonary arterial hypertension. J Cardiol. 2018 Jun 10. pii: S0914-5087(18)30137-0. doi: 10.1016/j.jjcc.2018.04.014. [Epub ahead of print] Review. PubMed PMID: 29898864.